PARIS, Feb. 9, 2016 /PRNewswire/ -- Sanofi (NYSE: SNY; EURONEXT: SAN)
Q4 2015 |
Change |
Change (CER) |
2015 |
Change |
Change (CER) |
|
Aggregate Group sales(1) |
€9,278m |
+2.3% |
-1.6% |
€37,057m |
+9.7% |
+2.2% |
Business net income(2) |
€1,709m |
-6.5% |
-13.5% |
€7,371m |
+7.7% |
-0.9% |
Business EPS(3) |
€1.31 |
-5.8% |
-12.9% |
€5.64 |
+8.5% |
0.0% |
(1) Including Animal Health Business, which is reported on a single line in the consolidated income statements in accordance with IFRS 5 (Non-current assets held for sale and discontinued operations). Additionally, Sanofi comments include Animal Health Business for every income statement line using "Aggregate" wording. (2) In order to facilitate an understanding of operational performance, Sanofi comments on the business net income statement. Business net income is a non-GAAP financial measure. (3) (EPS) Earnings Per Share. |
Experience the interactive Multimedia News Release here: http://www.multivu.com/players/English/7753751-sanofi-2015-annual-results/
Sanofi Chief Executive Officer, Olivier Brandicourt, commented:
"In 2015, Sanofi made meaningful progress with key launches, multiple business development activities and our efforts to simplify the organization. Entering into exclusive negotiations on a business swap with Boehringer Ingelheim would bring us leadership in CHC. This is a key first step in reshaping our portfolio. In 2016, we continue to allocate resources to our promising late-stage pipeline and the introduction of innovative medicines, which will position us for accelerated future growth."
Executing on 2020 strategic roadmap
Recent achievements in advancing Sanofi's R&D pipeline of innovative medicines
Sales growth in Pharmaceuticals, Vaccines and Animal Health in 2015
Solid financial results in 2015 while making significant investments in new product launches
2016 financial guidance
R&D Update
Regulatory update
Regulatory updates since the publication of the third quarter results on October 29, 2015 include the following:
At the beginning of February 2016, the R&D pipeline contained 46 pharmaceutical new molecular entities (excluding Life Cycle Management) and vaccine candidates in clinical development of which 14 are in Phase III or have been submitted to the regulatory authorities for approval.
Collaboration
To access the full press release of the 2015 annual results, please click here.
About Sanofi
Sanofi, a global healthcare leader, discovers, develops and distributes therapeutic solutions focused on patients' needs. Sanofi has core strengths in diabetes solutions, human vaccines, innovative drugs, consumer healthcare, emerging markets, animal health and Genzyme. Sanofi is listed in Paris (EURONEXT: SAN) and in New York (NYSE: SNY).
Sanofi is the holding company of a consolidated group of subsidiaries and operates in the United States as Sanofi US. For more information on Sanofi US, please visit http://www.sanofi.us and http://www.news.sanofi.us/social-media or call 1-800-981-2491.
Forward-Looking Statements
This press release contains forward-looking statements as defined in the Private Securities Litigation Reform Act of 1995, as amended. Forward-looking statements are statements that are not historical facts. These statements include projections and estimates and their underlying assumptions, statements regarding plans, objectives, intentions and expectations with respect to future financial results, events, operations, services, product development and potential, and statements regarding future performance. Forward-looking statements are generally identified by the words "expects", "anticipates", "believes", "intends", "estimates", "plans" and similar expressions. Although Sanofi's management believes that the expectations reflected in such forward-looking statements are reasonable, investors are cautioned that forward-looking information and statements are subject to various risks and uncertainties, many of which are difficult to predict and generally beyond the control of Sanofi, that could cause actual results and developments to differ materially from those expressed in, or implied or projected by, the forward-looking information and statements. These risks and uncertainties include among other things, the uncertainties inherent in research and development, future clinical data and analysis, including post marketing, decisions by regulatory authorities, such as the FDA or the EMA, regarding whether and when to approve any drug, device or biological application that may be filed for any such product candidates as well as their decisions regarding labelling and other matters that could affect the availability or commercial potential of such product candidates, the absence of guarantee that the product candidates if approved will be commercially successful, the future approval and commercial success of therapeutic alternatives, the Group's ability to benefit from external growth opportunities, trends in exchange rates and prevailing interest rates, the impact of cost containment initiatives and subsequent changes thereto, the average number of shares outstanding as well as those discussed or identified in the public filings with the SEC and the AMF made by Sanofi, including those listed under "Risk Factors" and "Cautionary Statement Regarding Forward-Looking Statements" in Sanofi's annual report on Form 20-F for the year ended December 31, 2014. Other than as required by applicable law, Sanofi does not undertake any obligation to update or revise any forward-looking information or statements.
Media Relations:
Mary Kathryn Steel
908-989-0726
[email protected]
Investor Relations:
George Grofik
908-981-5560
[email protected]
SOURCE Sanofi
Share this article